| Literature DB >> 11146439 |
G Schumacher1, E M Bruckheimer, A W Beham, T Honda, S Brisbay, J A Roth, C Logothetis, T J McDonnell.
Abstract
Adenoviral vectors expressing wild-type p53 (Ad-p53) induce apoptosis in different types of cancer cells. The therapeutic utility of Ad-p53 is now being evaluated in prostate-cancer patients. Bcl-2 is frequently expressed by prostate-cancer cells and has previously been shown to inhibit p53-mediated cell death following genotoxic stress. We studied the impact of bcl-2 on Ad-p53-induced cell death in human prostate-cancer cells. Human prostate-cancer cell lines LNCaP (p53 wt) and PC3 (p53 mut) were stably transfected with bcl-2. After p53 transduction, cell viability, apoptosis induction and modulation of specific apoptosis-regulatory proteins were assessed. LNCaP vector control and bcl-2-expressing cells underwent similar decreases in viability associated with apoptosis induction following Ad-p53 infection. Increased bcl-2 expression provided significant protection to PC3 cells transduced with Ad-p53. These findings are correlated with modulations in bax, bcl-2, bcl-x(L) and p21 protein levels. These data suggest that Ad-p53 may be useful in the treatment of some prostate cancers. Copyright 2001 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11146439 DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1026>3.3.co;2-e
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396